divided between outpatient and inpatient surgeries. Blood and blood product expenditures for Pennsylvania Hospital exceed $2.5 million per year. As expected, red blood cells comprise the significant majority of all costs associated with the blood bank expenditures (T8ble 1). Importantly, the costs shown are hos pital acquisition costs and do not include other costs associated with administration of blood products within the institution (ie, in-hospital administrative costs, typing, cross-matching).
The role of the chief executive officer (CEO) includes man aging budgetary expenditures and costs but also balancing issues related to patient safety and outcomes within the insti tution. Thus, the CEO is accountable to the staff, patients, and the public at large. Headlines regarding the US blood supply have appeared in various forms of media with increasing fre quency over the last several years: "safety not assured," "sup plies going down," "prices going up," and ''fears nmhigh." The current review will address these issues from the perspective of the hospital CEO.
KEY ISSUES RELATED TO BLOOD SUPPLY AND DEMAND
Without a doubt, the US blood supply is the safest in the world. Nevertheless, issues related to the blood supply impact patients and hospitals in a negative way. As advances to im prove the safety of the blood supply are implemented, costs associated with improvements in safety directly impact the hospital bottom line. For each incremental improvement in technology to maximize patient safety with respect to transfu sion, direct costs of the deliverable product have risen com mensurately. Nucleic acid testing for West Nile virus has added approximately $10 per unit of blood, whereas pathogen inac tivation adds $150 to $200 per unit (Fig 1) . In addition to the expenditures associated with the acquisition costs of blood and blood products, in-house costs (eg, blood bank administrative costs, type, and cross-match) must also be taken into account to determine the true cost of these products to the recipient When summating the in-house costs, the overall expenditure by a hospital to administer a unit of blood to a patient may be upwards of 3 times more than the base acquisition cost. By using the numbers assOciated with the Pennsylvania Hospital, the $2.5 million expenditure per year for blood and blood products may actually exceed $5 to 7 million per year in actual cost to the hospital in providing this intervention to the patient This large dollar amount is certain to capture the attention of the hospital CEO and warrants closer examination.
Another key issue of concern to the hospital CEO is the availability of blood and blood products. Because supplies of blood may be down throughout the country, subsequent re gional, then local, shortages may lead to cancellation of sur geries. Cancellation of surgery results in both patient and surgeon dissatisfaction in addition to increased hospital costs because the patient may spend an extra day(s) in the hospital awaiting adequate shipments of blood and blood products for the procedure. Furthermore, with an appreciation of the current blood supply, one must question overall readiness for the next big disaster. From the author's perspective, the answer is ''no, we are certainly not ready in the city of Philadelphia." In fact, the American Red Cross stopped blood delivery to hospitals in the area for a 3-to 4 cday period last summer, which resulted in very low and dangerous levels ofblood and blood products. As such, mechanisms to eliminate the effect of the tenuous blood supply on the activity of an individual institution must be considered. Furthermore, improved manageinent of blood and blood products by hospitals in general may help to alleviate supply issues nationally.
Patient safety with respect to transfusions and their related risks can be significant. Administrative errors, most of which occur outside the hospital blood bank, include patient identifi cation errors (37%), testing errors (18%), phlebotomy errors (13%), wrong unit issued (10%), wrong unit tagged (10%), incorrect order (5%), clerical error (2%), and miscellaneous error (8%). Errors such as these, particularly the significant incidence of patient identification errors, continue to occur lind often lead to patient morbidity and mortality. A CEO is con cerned not only for the welfare of the patient but also liability, malpractice filings, and claims paid within an institution. Liti gation and payout may severely impact the standing of the hospital within the community, including public relations con cerns. If the public loses confidence in the ability and safety record of the hospital, patients may choose other institutions for their health care.
SELLING A PROGRAM TO THE CEO
When approaching a CEO to establish a blood management, blood conservation, or bloodless medicine program, specific information is critical (Table 2) . For instance, a widely ac cepted technique for limiting blood utilization in certain sur geries is the institutional adoption of cell salvage. To imple ment institutionalization oftbis practice, clear advantages were conveyed to the CEO, such as using the patient's own blood, minimizing the cost of blood acquisition and testing, and min imizing the errors outlined previously. Even saving 2 to 2.5 units of blood or blood product per case may be very signifi cant. The disadvantages were also discussed, such as capital equipment outlay. A "break-even" point was determined; that is, the number of cases that must be perfmmed to cover the costs of the product, change in practice, or improved technol ogy. An assessment of the number of cases fully burdened Finally, skepticism and professional reluctance in changing established processes and procedures must be overcome. As such, development of other "supporting champions" to include nursing, phaImacy services, and house staff is very important. Growing public concern of blood safety Blood shortages Improved technology, devices, and pharmacologic agents Need to reduce health care costs Need to increase hospital revenues Improved physician skills and available techniques Improved patient care ExPanded hospital services to the community Need to reduce length of hospital stay Commitment to provide the best possible medical care Desire to stay on the cutting edge regarding blood conservation or bloodless medicine programs; they also order blood and blood products. Pharmacy may be asked to shoulder the cost of certain drug products· tbat·can offset the costs ofblood and blood produCts. For instance, agents such as the serine protease inhibitor aprotinin fall under the pharmacy budget, yet can reduce blood bank expenditures.
THE BEST APPROACH
The best approach is an internal one. A champion from within the institution is needed. usually an influential physiciali who cali spearhead the program. By using the blood conserva tion or bloodless medicine program approach, the champion should work with key health care practitioners and departments including surgery, anesthesiology, house ~ nursing, phar macy services, and labomtory medicine. In addition, or as an alternative approach, outside expertise may be sought. The culture of the hospital and/or timing of program development may dictate how this external support is brought fOl'WlU'd, depending on the particular environment within the institution. One may consider having a speaker address the key groups, a program director share their experience, or an outside consul tant guide the process. The consultant, for instance, can ask the 17S tough questions and work through difficult issues without get ting involved in the day-to-day interactions of the staff to miriimize undesirable working interactions.
The program must be evaluated as it is developing. Prelim inary results should be recorded. For instance, preliminary data at Pennsylvania Hospital indicate that the Bloodless Medicine Program has led to a 10% reduction in blood costs and a 13% reduction in length of stay. These are preliminary results, and they will be scrutinized as the program progresses. In addition,
improving patient care quality, minimizing errors, and control ling future costs are all parameters important to the CEO and will be assessed. Although caIdiac surgery (coronary artery bypass grafting, valve replacement) dominates surgical blood use in most insti tutions, major blood cost savings can be achieved in other settings. As such, the application of blood management ap pr:oa,chesshould. be· considered for other disciplines including . vascular surgery, orthopedic surgery (including spine), general surgery, and genitourinary surgery.
SUMMARY
Hospital CEOs are concerned about more than just costs of services to their patients. The advancement of patient care along with maintaining or improving patient safety are also key .
elements to the CEO, to limit patient risks, hospital liability, and negative public relations. The CEO is accountable to the hospital siatr, the patients, and the general public.
Establishing programs such as blood management or blood less medicine can be implemented by using a team approach. A physician·champion with a clear business plan that addresses all issues and challenges is critical for successful implementa tion. As blood and blood product costs rise and supply de creases, alternatives such as cell saving techniques and the use of pharmacologic interventions can have a significant impact on net hospital expenditures.
